verapamil has been researched along with Marfan Syndrome in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Marfan Syndrome: An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, A | 1 |
| Kenny, D | 1 |
| Wilson, D | 1 |
| Fagenello, G | 1 |
| Nelson, M | 1 |
| Dunstan, F | 1 |
| Cockcroft, J | 1 |
| Stuart, G | 1 |
| Fraser, AG | 1 |
| Jondeau, G | 1 |
| Barthelet, M | 1 |
| Baumann, C | 1 |
| Bonnet, D | 1 |
| Chevallier, B | 1 |
| Collignon, P | 1 |
| Dulac, Y | 1 |
| Edouard, T | 1 |
| Faivre, L | 1 |
| Germain, D | 1 |
| Khau Van Kien, P | 1 |
| Lacombe, D | 1 |
| Ladouceur, M | 1 |
| Lemerrer, M | 1 |
| Leheup, B | 1 |
| Lupoglazoff, JM | 1 |
| Magnier, S | 1 |
| Muti, C | 1 |
| Plauchu, PH | 1 |
| Raffestin, B | 1 |
| Sassolas, F | 1 |
| Schleich, JM | 1 |
| Sidi, D | 1 |
| Themar-Noël, C | 1 |
| Varin, J | 1 |
| Wolf, JE | 1 |
1 trial available for verapamil and Marfan Syndrome
| Article | Year |
|---|---|
Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Bloo | 2012 |
1 other study available for verapamil and Marfan Syndrome
| Article | Year |
|---|---|
[Recommendations for the medical management of aortic complications of Marfan's syndrome].
Topics: Adrenergic beta-Antagonists; Aortic Aneurysm; Aortic Dissection; Atenolol; Bisoprolol; Calcium Chann | 2006 |